Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821527 | 0.82 | NPSR1 (0.63) | MAPK1NPSR1PKMPAX8ATM | |
| SCHEMBL14409100 | 0.82 | PKM (0.49) | MAPK1NPSR1PKMPAX8ATM | |
| SCHEMBL12656711 | 0.75 | SMN1; SMN2 (0.60) | MAPK1NPSR1PKMATMMAPT | |
| SCHEMBL13065100 | 0.75 | LOXL2 (0.40) | MAPK1NPSR1PKMPAX8ATM | |
| SCHEMBL12656678 | 0.73 | MAPT (0.60) | MAPK1NPSR1MAPTALDH1A1CYP1A2 | |
| SCHEMBL12656928 | 0.72 | HTT (0.44) | MAPK1PAX8MAPTKDM4EALDH1A1 | |
| SCHEMBL5401241 | 0.72 | NR4A2 (0.50) | MAPK1NPSR1PKMPAX8ATM | |
| SCHEMBL12656896 | 0.72 | CASP3 (0.51) | MAPK1NPSR1ATMMAPTKDM4E | |
| SCHEMBL12657041 | 0.72 | NPC1 (0.60) | KDM4EALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL12656920 | 0.72 | NPC1 (0.46) | NPSR1PKMATMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316834-A1 | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316834-A1 | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1501829-B1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | VERTEX PHARMA (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7271179-B2 | Inhibitors of JAK protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271179-B2 | Inhibitors of JAK protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271179-B2 | Inhibitors of JAK protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1501829-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004058753-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040038992-A1 | Inhibitors of Jak protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038992-A1 | Inhibitors of Jak protein kinase | JAK2, JAK1, JAK3 | MAPK1 221/4885NPSR1 4523/4885PKM 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.